Ident. | Authors (with country if any) | Title |
---|
000033 (2021) |
Dania Altulea [Pays-Bas] ; Sjors Maassen [Pays-Bas] ; Maksim V. Baranov [Pays-Bas] ; Geert Van Den Bogaart [Pays-Bas] | What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. |
000051 (2021) |
Tahani Bin Ali ; Ghaleb Elyamany ; Maha Nojoom ; Mohamed Alfaki ; Hassan Alahmari ; Abdulwahab Alharthi ; Muwaffak Hijazi ; Atif Alsahari ; Fahad Alabbas ; Abdulnasir Al-Otaibi [Arabie saoudite] | Unusual presentation of COVID-19 in a child complicated by massive acute pulmonary embolism and lung infarction. |
000056 (2021) |
Jessica S C. Leung [Hong Kong] ; Maurice M W. Cheng [Nouvelle-Zélande] | Trust in the time of corona: epistemic practice beyond hard evidence. |
000069 (2021) |
Waqas Aslam [Oman] ; Carla R. Lamb [États-Unis] ; Nadia Ali [États-Unis] | Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. |
000094 (2021) |
Subham Das [Inde] ; Anu Kunnath Ramachandran [Inde] ; Sumit Raosaheb Birangal [Inde] ; Saleem Akbar [Inde] ; Bahar Ahmed [Inde] ; Alex Joseph [Inde] | The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. |
000105 (2021) |
Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban] | The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. |
000107 (2021) |
O O Oleribe [Nigeria] ; P. Oskouipour [États-Unis] ; O. Nwanyanwu [États-Unis] ; S D Taylor-Robinson [Royaume-Uni] | The COVID-19 era: the view from Nigeria. |
000117 (2021) |
Tesia Bobrowski [États-Unis] ; Lu Chen [États-Unis] ; Richard T. Eastman [États-Unis] ; Zina Itkin [États-Unis] ; Paul Shinn [États-Unis] ; Catherine Z. Chen [États-Unis] ; Hui Guo [États-Unis] ; Wei Zheng [États-Unis] ; Sam Michael [États-Unis] ; Anton Simeonov [États-Unis] ; Matthew D. Hall [États-Unis] ; Alexey V. Zakharov [États-Unis] ; Eugene N. Muratov [États-Unis] | Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. |
000127 (2021) |
Thirumal Kumar D [Inde] ; Nishaat Shaikh [Inde] ; Udhaya Kumar S [Inde] ; George Priya Doss C [Inde] ; Hatem Zayed [Qatar] | Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2. |
000172 (2021) |
Fanny Onodi [France] ; Lucie Bonnet-Madin [France] ; Laurent Meertens [France] ; Léa Karpf [France] ; Justine Poirot [France] ; Shen-Ying Zhang [France, États-Unis] ; Capucine Picard [France] ; Anne Puel [France, États-Unis] ; Emmanuelle Jouanguy [France, États-Unis] ; Qian Zhang [États-Unis] ; Jérôme Le Goff [France] ; Jean-Michel Molina [France] ; Constance Delaugerre [France] ; Jean-Laurent Casanova [France, États-Unis] ; Ali Amara [France] ; Vassili Soumelis [France] | SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4. |
000173 (2021) |
Fanny Onodi [France] ; Lucie Bonnet-Madin [France] ; Laurent Meertens [France] ; Léa Karpf [France] ; Justine Poirot [France] ; Shen-Ying Zhang [États-Unis] ; Capucine Picard ; Anne Puel [États-Unis] ; Emmanuelle Jouanguy [États-Unis] ; Qian Zhang [États-Unis] ; Jérôme Le Goff [France] ; Jean-Michel Molina [France] ; Constance Delaugerre [France] ; Jean-Laurent Casanova [États-Unis] ; Ali Amara [France] ; Vassili Soumelis [France] | SARS-CoV-2 induces human plasmacytoid pre-dendritic cell diversification via UNC93B and IRAK4. |
000183 (2021) |
Byung Jin Choi [Corée du Sud] ; Yeryung Koo [Corée du Sud] ; Tae Young Kim [Corée du Sud] ; Wou Young Chung [Corée du Sud] ; Yun Jung Jung [Corée du Sud] ; Ji Eun Park [Corée du Sud] ; Hong-Seok Lim [Corée du Sud] ; Bumhee Park [Corée du Sud] ; Dukyong Yoon [Corée du Sud] | Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. |
000220 (2021) |
Mengmeng Zhao [République populaire de Chine] ; Jishou Zhang [République populaire de Chine] ; Hanli Li [République populaire de Chine] ; Zhen Luo [République populaire de Chine] ; Jing Ye [République populaire de Chine] ; Yao Xu [République populaire de Chine] ; Zhen Wang [République populaire de Chine] ; Di Ye [République populaire de Chine] ; Jianfang Liu [République populaire de Chine] ; Dan Li [République populaire de Chine] ; Menglong Wang [République populaire de Chine] ; Jun Wan [République populaire de Chine] | Recent progress of antiviral therapy for coronavirus disease 2019. |
000227 (2021) |
Iwein Gyselinck [Belgique] ; Wim Janssens [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] | Rationale for azithromycin in COVID-19: an overview of existing evidence. |
000248 (2021) |
Alberto Castagna ; Giovanni Ruotolo ; Ciro Manzo | Progress in the risk assessment of hydroxychloroquine in frail elderly people. |
000249 (2021) |
Bianza Moise Bakadia ; Feng He [République populaire de Chine] ; Tiatou Souho [Togo] ; Lallepak Lamboni [Togo] ; Muhammad Wajid Ullah [République populaire de Chine] ; Biaou Ode Boni [République populaire de Chine] ; Abeer Ahmed Qaed Ahmed [République populaire de Chine] ; Biampata Mutu Mukole ; Guang Yang [République populaire de Chine] | Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. |
000264 (2021) |
Yanqiang Han ; Zhilong Wang ; Jiahao Ren ; Zhiyun Wei ; Jinjin Li [République populaire de Chine] | Potential inhibitors for the novel coronavirus (SARS-CoV-2). |
000291 (2021) |
Eleni Karatza [Grèce] ; George Ismailos [Grèce] ; Markos Marangos [Grèce] ; Vangelis Karalis [Grèce] | Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. |
000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
000299 (2021) |
Marko Boban [Croatie] | Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. |
000307 (2021) |
Shweta A. More [Inde] ; Akshay S. Patil [États-Unis] ; Nikhil S. Sakle [Inde] ; Santosh N. Mokale [Inde] | Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. |